ClinicalTrials.gg
TerminatedNCT01247207Updated Oct 8, 2026Results posted

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

A Phase 3 interventional study of Ataluren in Duchenne Muscular Dystrophy, sponsored by PTC Therapeutics. Terminated at 34 sites in 2 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision
Updated Oct 8, 2026Now TerminatedResults posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
265
Allocation
Not applicable
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing ataluren in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. ataluren · Muscular Dystrophy, Duchenne.

Enrollment
2nd of 14
265 · median 66
Started
2010
with 1 other
Phase 3
5 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
14 of 14
PTC Therapeutics

Among the 14 studies testing ataluren in Muscular Dystrophy, Duchenne, this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 3, and was the 6th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 14 studies testing ataluren in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About ataluren

ataluren: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing ataluren in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The objective of this study is to assess the safety and tolerability of 10, 10, 20 milligrams per kilogram (mg/kg) ataluren in participants with nmDBMD who had prior exposure to ataluren in a PTC sponsored clinical trial or treatment plan, and siblings of those participants (provided those participants have completed the placebo-controlled portion of the trial).

The treatment will continue under this protocol until consent withdrawal by participants, withdrawal due to worsen condition after initiating ataluren treatment, withdrawal by investigator, withdrawal due to participant unable to tolerate ataluren, participant is eligible to participate in another ataluren nmDBMD clinical trial program initiated by sponsor, study is discontinued by the relevant regulatory authority and/or sponsor, or until ataluren becomes commercially available.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne muscular dystrophy
  • Becker muscular dystrophy
  • Nonsense mutation
  • Premature stop codon
  • DMD
  • BMD
  • nmDBMD
  • DBMD
  • Ataluren
  • PTC124
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of signed and dated /assent document(s) indicating that the participant (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial. Note: If the study candidate is considered a child under local regulation, a parent or legal guardian must provide written consent prior to initiation of study screening procedures and the study candidate may be required to provide written assent. The rules of the responsible Institutional Review Board/Independent Ethic Committee (IRB/IEC) regarding whether one or both parents must provide consent and the appropriate ages for obtaining consent and assent from the participant should be followed.
  • History of exposure to ataluren in a prior PTC study or treatment plan and effected nmDBMD siblings of those participants (provided those participants have completed the placebo-controlled portion of the trial).
  • Fertile men, who are sexually active with women of and who have not had a vasectomy, must agree to use a barrier method of during the study and for up to 50 days after the last dose of study drug.
  • Willingness and ability to comply with scheduled visits, drug administration and return plan, study procedures, laboratory tests, and study restrictions Note: Psychological, social, familial, or geographical factors that might preclude adequate study participation should be considered.

Exclusion criteria

Exclusion Criteria:

  • Exposure to another drug within 1 month prior to start of study treatment.
  • Eligibility for another ataluren clinical trial that is actively enrolling study participants.
  • Positive for core antibody or antibody at screening for ataluren naïve participants (siblings) or participants who have a temporary treatment gap of 1 year before entering study
  • Known to any of the ingredients or of ataluren (refined polydextrose, polyethylene glycol 3350, poloxamer 407, mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, colloidal silica, magnesium stearate).
  • Ongoing intravenous (IV) aminoglycoside or IV vancomycin therapy.
  • Ongoing uncontrolled medical/surgical condition, (ECG) findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the participant or make it unlikely that follow-up would be completed.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
265 participants (actual)

Study arms

  • Experimental
    Ataluren

    Participants will receive 3 doses of ataluren oral suspension per day (10 mg/kg in the morning, 10 mg/kg at mid-day and 20 mg/kg in the evening).

    Drug: Ataluren

Interventions

  • Ataluren will be administered as per the dose and schedule specified in the arm.

    Also known as: PTC124, Translarna

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline up to end of study (up to approximately 15 years)

07

Results

Posted Oct 8, 2026
Limitations and caveats
The study was terminated early due to Sponsor's decision.

Participant flow

Participant flow — Overall Study
MilestoneAtaluren
Started265
Received at least 1 dose of study drug265
Completed0
Not completed265
Withdrew: Adverse event29
Withdrew: Lost to follow-up16
Withdrew: Withdrawal by subject67
Withdrew: Investigator decision5
Withdrew: Protocol violation5
Withdrew: Study termination111
Withdrew: Other than specified32

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as an AE that occurred or worsened on or after the first dose of ataluren and up to 4 weeks after the last dose of ataluren. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline up to end of study (up to approximately 15 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsAtaluren
Number of Participants With Treatment-emergent Adverse Events (TEAEs)242

Adverse events

Collected over Baseline up to end of study (up to approximately 15 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ataluren14/265 (5.3%)90/265 (34%)241/265 (90.9%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventAtaluren
Femur fractureInjury, poisoning and procedural complications26/265
PneumoniaInfections and infestations18/265
InfluenzaInfections and infestations6/265
DehydrationMetabolism and nutrition disorders5/265
Respiratory failureRespiratory, thoracic and mediastinal disorders5/265
Cardiac failureCardiac disorders4/265
SepsisInfections and infestations4/265
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/265
Cardiac arrestCardiac disorders3/265
Compression fractureInjury, poisoning and procedural complications3/265
Most frequent other events
Showing 10 of 38
Most frequent other events
EventAtaluren
NasopharyngitisInfections and infestations94/265
Disease progressionGeneral disorders59/265
COVID-19Infections and infestations54/265
VomitingGastrointestinal disorders51/265
FallInjury, poisoning and procedural complications47/265
CoughRespiratory, thoracic and mediastinal disorders46/265
DiarrhoeaGastrointestinal disorders45/265
HeadacheNervous system disorders43/265
PyrexiaGeneral disorders42/265
InfluenzaInfections and infestations42/265

Baseline characteristics

The As-treated population included all participants who received at least 1 dose of ataluren.

Age, Continuous
Age, Continuous(years)Ataluren
Mean10.9 ± 3.99
Sex: Female, Male
Sex: Female, Male(Participants)Ataluren
Female0
Male265
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ataluren
Hispanic or Latino20
Not Hispanic or Latino119
Unknown or Not Reported126
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ataluren
Race — Asian20
Race — Black or African American8
Race — White205
Race — Other22
Race — Missing10
08

Study locations

34 sites
  • Phoenix Childrens Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
  • UCLA
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • University of California-Davis
    Sacramento, California 95817, United States
  • University of CA, San Francisco-Benioff Children's Hospital
    San Francisco, California 94158, United States
  • Children's Hospital Colorado - Center for Cancer and Blood Disorders
    Aurora, Colorado 80045, United States
  • Child Neurology Center of NW Florida NW
    Gulf Breeze, Florida 32561, United States
  • Rare Disease Research, LLC
    Atlanta, Georgia 30329, United States
  • Rush Univ Medical Center
    Chicago, Illinois 60612, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Children's Hospital of Boston/Harvard Medical School
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Washington University Medical School
    St Louis, Missouri 63110, United States
  • Columbia University Pediatric Neuromuscular Center
    New York, New York 10032, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Shriners Hospital for Children-Portland
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 16148, United States
  • Childrens Medical Center Dallas
    Dallas, Texas 75207, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Children's Hospital of the King's Daughters
    Norfolk, Virginia 23507, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Alberta Children's Hospital
    Calgary, Alberta, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia, Canada
  • London Health Sciences Centre
    London, Ontario, Canada
  • Children's Hospital of East Ontario
    Ottawa, Ontario, Canada
  • CHU de Québec - Université Laval
    Québec, Canada
09

References and documents

Publications

  • Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007 Apr;47(4):430-44. doi: 10.1177/0091270006297140. PubMed 17389552 ↗
  • Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007 May 3;447(7140):87-91. doi: 10.1038/nature05756. Epub 2007 Apr 22. PubMed 17450125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2010 to primary completion in Feb 2026, 182 months.

Results were first posted in Oct 2026, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2010
First posted
Nov 24, 2010
StartActual
Nov 22, 2010
Primary completionActual
Feb 10, 2026
CompletionActual
Feb 10, 2026
Results first posted
Oct 8, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated Sponsor decision
changed Oct 8, 2026
Results
Results posted
posted Oct 8, 2026
Start date
Nov 30, 2010→Nov 22, 2010
Oct 8, 2026
Enrollment
270 (estimated)→265 (actual)
Oct 8, 2026
Primary outcomes
1 edited, 2 removed
What changed in the outcomes
  • EditedNumber of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to end of study (up to approximately 8 years) → Baseline up to end of study (up to approximately 15 years)
  • RemovedNumber of Participants With Laboratory Parameters AbnormalitiesTime frame: Baseline up to end of study (up to approximately 8 years)
  • RemovedNumber of Participants With Abnormal Physical FindingsTime frame: Baseline up to end of study (up to approximately 8 years)
Oct 8, 2026
Documents
Show all 1 update
  1. Oct 8, 2026
    Completed→Terminated
    Why stopped Sponsor decision
    Results posted
    Start date Nov 30, 2010→Nov 22, 2010
    Enrollment 270 (estimated)→265 (actual)
    Primary outcomes 1 edited, 2 removed
    What changed in the outcomes
    • EditedNumber of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to end of study (up to approximately 8 years) → Baseline up to end of study (up to approximately 15 years)
    • RemovedNumber of Participants With Laboratory Parameters AbnormalitiesTime frame: Baseline up to end of study (up to approximately 8 years)
    • RemovedNumber of Participants With Abnormal Physical FindingsTime frame: Baseline up to end of study (up to approximately 8 years)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT01247207
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Nov 24, 2010
Start date
Nov 22, 2010
Primary completion
Feb 10, 2026
Completion
Feb 10, 2026
Results posted
Oct 8, 2026
Last update
Oct 8, 2026

Study contacts

Vinay Penematsa, MD
study director · PTC Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ataluren

Start the discussion